Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Paraganglioma diagnosed by EBUS-TBNA: A case report].

Created on 22 Sep 2026

Authors

G Perceval, G Riley, L Schnedecker, J Staentzel, G Treffel

Published in

Revue des maladies respiratoires. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

Paragangliomas are rare neuroendocrine tumors occasionally found in the mediastinum. A characteristic CT presentation suffices to raise suspicions. Biopsy specimens are usually avoided, and diagnosis is generally based on a combination of biological, clinical and iconographic evidence.
We report on the case of an 84-year old female patient without adrenergic signs, who presented with an isolated mid-mediastinal lesion, which was found on FDG-TEP to be hypermetabolic. Its appearance was suggestive of a neuroendocrine tumor or a clear cell renal tumor, leading to investigation by EBUS-TBNA. The cytology aspirations subsequently performed were complicated by moderate bleeding, which was controlled by local instillations of adrenalized serum. An anatomopathological diagnosis of paraganglioma ensued, and was confirmed by further endocrinologic investigations.
Notwithstanding its technical feasibility, assessment of mediastinal paragangliomas by EBUS-TBNA may present an increased risk of moderate to severe bleeding. Appropriate safety measures should be considered, as well as diagnosis by non-invasive methods alone.

PMID:
42767900
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement